Word: arcoxia
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...will be looking closely for similar risks when the next three COX-2 inhibitors in the pipeline--Merck's Arcoxia, Pfizer's Dynastat and Novartis' Prexige--come up for review in a few years. This time they hope to discover potential problems before the drugs are approved, not after. --By Alice Park
...Pfizer's Celebrex has been studied the longest; some patients in three ongoing Celebrex trials have been followed for several years without any signs of cardiovascular effects. Bextra, also from Pfizer, hasn't been tested as long, but so far the data look good. Two more COX-2 inhibitors, Arcoxia (from Merck) and Prexige (from Novartis), are awaiting FDA approval. "Obviously, we now have to look more carefully at the other members of the class," says Dr. Steven Nissen, a cardiologist at the Cleveland Clinic who voiced his concerns about Vioxx several years...
| 1 |